Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2016

View Archived Issues

BioLineRx in-licenses liver fibrosis drug candidate

Novartis patents angiotensin receptor antagonists

University of Occupational and Environmental Health and Yakult Honsha disclose ZNF143 inhibitors

Evelo Biosciences, Mayo Clinic to collaborate on immuno-microbiome-based therapies for cancer

Pivotal phase III ATLANTIS study of PharmaMar's lurbinectedin begins

FDA grants orphan drug designation to Agilis Biotherapeutics' AGIL-FA

REGENXBIO's RGX-121 wins FDA rare pediatric disease designation

Divestiture of Allergan's generic business to Teva complete

Long-term safety of CERE-120 in patients with Parkinson's disease

Meda shareholders accept Mylan offer

Regeneron and Adicet Bio enter collaboration to develop next-generation immune cell therapeutics

ContraVir Pharmaceuticals' tenofovir analogue for HBV safe and well tolerated in phase Ib study

Daiichi Sankyo profiles pipeline progress of first quarter of fiscal 2016

AbbVie reports key events from second quarter 2016

GeoVax awarded contract from NIH to further develop HIV vaccine

BARDA awards contract to Altimmune for anthrax vaccine candidate

Abeona Therapeutics gives update on phase I/II study of MPS IIIA treatment

HTIT makes milestone payment to Oramed for oral insulin product

Shionogi transfers 21 long-listed drugs to Lupin's subsidiary Kyowa in Japan

Novartis' LEE-011 receives FDA breakthrough therapy designation

Keytruda approved in Europe for patients with advanced NSCLC whose tumors express PD-L1

Human commensals found to produce a novel antibiotic

CDC Zika MAC-ELISA test now available to commercial laboratories

Activity of secukinumab on brain lesions in RRMS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...